AIM: To explore efficacy of intravitreous injection of Bevacizumab combined with trabeculectomy and glaucoma valve implantation in patients with neovascular glaucoma.

METHODS: Totally 22 patients(23 eyes)with neovascular glaucoma from May 2008 to May 2010 were analyzed retrospectively. All patients were treated with intravitreous injection of Bevacizumab. After 3-5d, 13 eyes were treated with glaucoma valve implantation(group A)and 10 eyes were treated with trabeculectomy(group B). The period of follow-up was 12-26mo. The postoperative visual acuity, intraocular pressure, iris neovascularization and complication rate were compared between the two groups.

RESULTS: Iris neovascularization in group A and group B decreased or completely disappeared after 3-5d intravitreous injection of Bevacizumab. The success rate was 100%. The ratio of improved visual acuity in group A was significantly higher than that of group B(P<0.05), what's more, visual acuity of one patient decreased in group B. Compared with that before operation, intraocular pressure in group A and group B significantly decreased(P<0.05), but the average of intraocular pressure in group A was lower than that of group B during the long term follow-up(P<0.05). Complication rate had no statistical difference between group A and group B(P>0.05).

CONCLUSION: Intravitreous injection of Bevacizumab combined with glaucoma valve implantation is worth clinical application for improving visual acuity. Compared with trabeculectomy, it can control intraocular pressure better and reduce complication in patients with neovascular glaucoma.